BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35641882)

  • 1. Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis.
    Singini MG; Singh E; Bradshaw D; Ramaliba T; Chen WC; Motlhale M; Kamiza AB; Babb de Villiers C; Muchengeti M; Mathew CG; Newton R; Bender N; Waterboer T; Sitas F
    J Med Virol; 2023 Jan; 95(1):e27900. PubMed ID: 35641882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
    Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer.
    Zhang JJ; Cao XC; Zheng XY; Wang HY; Li YW
    J Int Med Res; 2018 Mar; 46(3):1033-1042. PubMed ID: 29322839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical effect evaluation of high risk human papilloma virus E6/E7 mRNA in triaging women with atypical squamous cells of undetermined significance].
    Guo Z; Zhao DM; Zhang SK; Wu ZN; Sun XB; Jia MM; Chen Q; Guo LW; Chen PP; Zhang JG
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1094-1099. PubMed ID: 34695901
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
    Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
    PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
    Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
    Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.
    Beachler DC; Viscidi R; Sugar EA; Minkoff H; Strickler HD; Cranston RD; Wiley DJ; Jacobson LP; Weber KM; Margolick JB; Reddy S; Gillison ML; D'Souza G
    Sex Transm Dis; 2015 Feb; 42(2):93-7. PubMed ID: 25585068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women.
    Bruno MT; Ferrara M; Fava V; Rapisarda A; Coco A
    Virol J; 2018 Mar; 15(1):52. PubMed ID: 29587778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of HPV 16 and HPV 18 Oncoprotein Expression as Alternative Diagnostic Tools in Cervical Lesion.
    Sabri NA; Shamsuddin SH; Mat Zin AA
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):521-527. PubMed ID: 38415538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
    Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
    Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.
    Galati L; Combes JD; Le Calvez-Kelm F; McKay-Chopin S; Forey N; Ratel M; McKay J; Waterboer T; Schroeder L; Clifford G; Tommasino M; Gheit T
    Microbiol Spectr; 2022 Apr; 10(2):e0148021. PubMed ID: 35225653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
    Combes JD; Pawlita M; Waterboer T; Hammouda D; Rajkumar T; Vanhems P; Snijders P; Herrero R; Franceschi S; Clifford G
    Int J Cancer; 2014 Nov; 135(10):2453-61. PubMed ID: 24729277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis.
    Downham L; Jaafar I; Rol ML; Nyawira Nyaga V; Valls J; Baena A; Zhang L; Gunter MJ; Arbyn M; Almonte M
    Br J Cancer; 2024 Mar; 130(4):517-525. PubMed ID: 37973957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Variability in the E6, E7, and L1 Genes of Human Papillomavirus Types 16 and 18 among Women in Saudi Arabia.
    Alsanea M; Alsaleh A; Obeid D; Alhadeq F; Alahideb B; Alhamlan F
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
    Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
    PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
    Wang HY; Kim H; Park KH
    Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.